# A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment

> **NCT04233190** · PHASE3 · COMPLETED · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 472 (actual)

## Conditions studied

- Asthma Copd

## Interventions

- **DRUG:** Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg

## Key facts

- **NCT ID:** NCT04233190
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-19
- **Primary completion:** 2024-10-28
- **Final completion:** 2024-10-30
- **Target enrollment:** 472 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233190, "A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04233190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*